EZETIMIBE vs Rosuvastatin

Compare EZETIMIBE (EZETIMIBE) and Rosuvastatin (Crestor) — clinical data, side effects, and patient experiences.

EZETIMIBE

EZETIMIBE, Zetia · Cholesterol Absorption Inhibitor

How it works

12.1 Mechanism of Action Ezetimibe reduces blood cholesterol by inhibiting the absorption of cholesterol by the small intestine. The molecular target of ezetimibe has been shown to...

Approved for

1 INDICATIONS AND USAGE Ezetimibe tablets are indicated: • In combination with a statin

or alone when additional low-density lipoprotein cholesterol (LDL-C) lowering therapy is not possible

as an adjunct to diet to reduce elevated LDL-C in adults with primary hyperlipidemia

and other LDL-C lowering therapies

OralTablet

Rosuvastatin

Crestor · HMG-CoA Reductase Inhibitor (Statin)

How it works

Competitively inhibits HMG-CoA reductase with high affinity. More hydrophilic than atorvastatin, with greater LDL-C lowering potency on a milligram basis.

Approved for

Hyperlipidemia

Primary prevention of cardiovascular disease

Familial hypercholesterolemia

t½: 19 hoursFDA: 2003OralTablet

Quick Comparison

EZETIMIBERosuvastatin

Drug Class

Cholesterol Absorption Inhibitor

HMG-CoA Reductase Inhibitor (Statin)

Route

Oral

Half-Life

—

19 hours

FDA Approved

—

2003

Pregnancy

—

Efficacy Rating

0.0/10

10.0/10

Tolerability

0.0/10

8.0/10

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

EZETIMIBE

Fatigue

1-10%

Nausea

1-10%

Muscle Pain

1-10%

Drug Not Working

1-10%

Diarrhea

1-10%

Dizziness

1-10%

Shortness of Breath

1-10%

Headache

1-10%

Rosuvastatin

Muscle Pain

1-10%

Headache

1-10%

FDA Warnings

EZETIMIBE

5 WARNINGS AND PRECAUTIONS • Risks Associated with Combination Treatment with a Statin, Fenofibrate, or Other LDL-C Lowering Therapies : Refer to the Prescribing Information of these products for a description of their risks including, but not limited to, the warnings and precautions
In post-marketing reports, most patients who developed rhabdomyolysis were taking a statin or other agents known to be associated with an increased risk of rhabdomyolysis, such as fibrates
1 Risks Associated with Combination Treatment with a Statin, Fenofibrate, or Other LDL-C Lowering Therapies If ezetimibe is administered with a statin, fenofibrate, or other LDL-C lowering therapies, refer to the Prescribing Information of these products for a description of their risks including, but not limited to, the warnings and precautions [see Contraindications (4) ]
In post-marketing reports, most patients who developed rhabdomyolysis were taking a statin or other agents known to be associated with an increased risk of rhabdomyolysis, such as fibrates

Rosuvastatin

Rhabdomyolysis risk
Proteinuria and hematuria at high doses
Hepatotoxicity

Community Sentiment Analysis

Based on 3 Reddit discussions

EZETIMIBE

33%

positive

3 threads

Rosuvastatin

positive

0 threads

Head-to-Head Ratings

Patient Real-World Experience

Based on 1 verified patient review

EZETIMIBE (0)

Rosuvastatin (1)

Efficacy

0.0/1010.0/10

Tolerability

0.0/108.0/10

Overall Satisfaction

0.0/109.0/10

EZETIMIBE Side Effects

No data yet

Rosuvastatin Side Effects

No data yet

Avg. Duration

0 months

0% still taking

Avg. Duration

24 months

100% still taking

EZETIMIBE vs Rosuvastatin: What You Should Know

Key Differences

EZETIMIBE is a Cholesterol Absorption Inhibitor, while Rosuvastatin belongs to the HMG-CoA Reductase Inhibitor (Statin) class. This means they work through different pharmacological mechanisms, which may influence both efficacy and side effect profiles.

Patient Experience

Rosuvastatin has an average efficacy rating of 10.0/10 and tolerability of 8.0/10 across 1 patient review. Patient-reported outcomes provide real-world context beyond clinical trials, though individual responses to medication vary significantly..

Safety Considerations

EZETIMIBE carries 4 FDA warnings. Rosuvastatin carries 3 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

Atorvastatin vs Rosuvastatin→BEMPEDOIC ACID AND EZETIMIBE vs EZETIMIBE→Atorvastatin vs EZETIMIBE→Rosuvastatin vs SIMVASTATIN→PITAVASTATIN vs Rosuvastatin→ALIROCUMAB vs Rosuvastatin→

Loading comparison data...

EZETIMIBE vs Rosuvastatin

Compare EZETIMIBE (EZETIMIBE) and Rosuvastatin (Crestor) — clinical data, side effects, and patient experiences.

EZETIMIBE

EZETIMIBE, Zetia · Cholesterol Absorption Inhibitor

How it works

12.1 Mechanism of Action Ezetimibe reduces blood cholesterol by inhibiting the absorption of cholesterol by the small intestine. The molecular target of ezetimibe has been shown to...

Approved for

1 INDICATIONS AND USAGE Ezetimibe tablets are indicated: • In combination with a statin

or alone when additional low-density lipoprotein cholesterol (LDL-C) lowering therapy is not possible

as an adjunct to diet to reduce elevated LDL-C in adults with primary hyperlipidemia

and other LDL-C lowering therapies

OralTablet

Rosuvastatin

Crestor · HMG-CoA Reductase Inhibitor (Statin)

How it works

Competitively inhibits HMG-CoA reductase with high affinity. More hydrophilic than atorvastatin, with greater LDL-C lowering potency on a milligram basis.

Approved for

Hyperlipidemia

Primary prevention of cardiovascular disease

Familial hypercholesterolemia

t½: 19 hoursFDA: 2003OralTablet

Quick Comparison

EZETIMIBERosuvastatin

Drug Class

Cholesterol Absorption Inhibitor

HMG-CoA Reductase Inhibitor (Statin)

Route

Oral

Half-Life

—

19 hours

FDA Approved

—

2003

Pregnancy

—

Efficacy Rating

0.0/10

10.0/10

Tolerability

0.0/10

8.0/10

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

EZETIMIBE

Fatigue

1-10%

Nausea

1-10%

Muscle Pain

1-10%

Drug Not Working

1-10%

Diarrhea

1-10%

Dizziness

1-10%

Shortness of Breath

1-10%

Headache

1-10%

Rosuvastatin

Muscle Pain

1-10%

Headache

1-10%

FDA Warnings

EZETIMIBE

5 WARNINGS AND PRECAUTIONS • Risks Associated with Combination Treatment with a Statin, Fenofibrate, or Other LDL-C Lowering Therapies : Refer to the Prescribing Information of these products for a description of their risks including, but not limited to, the warnings and precautions
In post-marketing reports, most patients who developed rhabdomyolysis were taking a statin or other agents known to be associated with an increased risk of rhabdomyolysis, such as fibrates
1 Risks Associated with Combination Treatment with a Statin, Fenofibrate, or Other LDL-C Lowering Therapies If ezetimibe is administered with a statin, fenofibrate, or other LDL-C lowering therapies, refer to the Prescribing Information of these products for a description of their risks including, but not limited to, the warnings and precautions [see Contraindications (4) ]
In post-marketing reports, most patients who developed rhabdomyolysis were taking a statin or other agents known to be associated with an increased risk of rhabdomyolysis, such as fibrates

Rosuvastatin

Rhabdomyolysis risk
Proteinuria and hematuria at high doses
Hepatotoxicity

Community Sentiment Analysis

Based on 3 Reddit discussions

EZETIMIBE

33%

positive

3 threads

Rosuvastatin

positive

0 threads

Head-to-Head Ratings

Patient Real-World Experience

Based on 1 verified patient review

EZETIMIBE (0)

Rosuvastatin (1)

Efficacy

0.0/1010.0/10

Tolerability

0.0/108.0/10

Overall Satisfaction

0.0/109.0/10

EZETIMIBE Side Effects

No data yet

Rosuvastatin Side Effects

No data yet

Avg. Duration

0 months

0% still taking

Avg. Duration

24 months

100% still taking

EZETIMIBE vs Rosuvastatin: What You Should Know

Key Differences

Patient Experience

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.